Vicken Karageozian, MD, President & CEO speaks for Allegro Ophthalmics during the Innovative Showcase at OIS@ASRS 2019. REGISTER for our next ophthalmology conference today [ Ссылка ].
Vicken Karageozian, MD, President & CEO gives an update on Allegro Ophthalmic’s anti-integrin program in both front and back of the eye diseases. Their lead asset in retina is risuteganib, which has completed a Phase 2 study in dry AMD and two Phase 2 studies in diabetic macular edema. And for the front of the eye the company has ALG-1007, a topical eye drop for dry eye disease. Pre-clinical work done in independent labs shows that in retina, there is a robust anti-complement 3 effect, a reduction of mitochondrial reactive oxygen species, and improvement of mitochondrial bioenergetics. This means that if you can catch retinal tissue while still viable but offline, you can bring it back online, and recover visual function. The Phase 2 study was performed in 7 sites in the United States with treatment over 32 weeks. The primary endpoint was 8 letters or greater BCVA gain, which was met. Other efficacy endpoints are still being evaluated. ALG-1007 works by inhibiting T-cell attachment and migration across the cornea. This has undergone a single site does-escalation study outside the U.S. that showed a robust efficacy signal. A phase 2 study is ongoing.
This presentation takes place at OIS@ASRS at the Ritz-Carlton in Chicago on July 25, 2019.
Download the presentation here: [ Ссылка ]
WEBSITE
[ Ссылка ]
FOLLOW Ophthalmology Innovation Summit On Social Media:
► Facebook: [ Ссылка ]
► Twitter: [ Ссылка ]
JOIN Our Group For Ophthalmology Innovation & Investment On LinkedIn
[ Ссылка ]
SUBSCRIBE To Our Weekly OIS Newsletter
[ Ссылка ]
VIEW Our Past Ophthalmology Event Conferences:
[ Ссылка ]
REGISTER For Our Next Conference:
[ Ссылка ]
#OIS #Ophthalmology #Healthcare
_________________________________________________________________
About OIS
Ophthalmology Innovation Summit, or OIS for short, facilitates meaningful interactions and the exchange of information between clinical, capital, and corporate leaders to accelerate the development and commercialization of novel therapies to address unmet needs.
The Ophthalmology Innovation Summit programs are presented annually by Healthegy, Inc. as affiliate meetings with American Academy of Ophthalmology (AAO), American Society of Cataract and Refractive Surgery (ASCRS), Southeastern Congress of Optometry (SECO), and American Society of Retina Specialists (ASRS).
____________________________________________________________________
Healthegy also is the producer of Aesthetics Innovation Summit (AIS), which unites the clinical, corporate and capital leaders to facilitate the exchange of insights on emerging trends while showcasing exciting new drugs, devices, and technologies for the aesthetics market which is projected to double by 2025.
► Website: [ Ссылка ]
► Facebook: [ Ссылка ]
► Instagram: [ Ссылка ]
► Twitter: [ Ссылка ]
► Healthegy Website: [ Ссылка ]
